HHS OIG Issues Guidance on Anti-Kickback Statute Implications for Direct-to-Consumer Drug Sales Ahead of TrumpRx Launch (JSON)

lexblog.com/lib/NRCPX2BYview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "HHS OIG Issues Guidance on Anti-Kickback Statute Implications for Direct-to-Consumer Drug Sales Ahead of TrumpRx Launch",
    "url": "https://www.lexblog.com/2026/02/05/hhs-oig-issues-guidance-on-anti-kickback-statute-implications-for-direct-to-consumer-drug-sales-ahead-of-trumprx-launch/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-NRCPX2BY",
        "url": "https://www.lexblog.com/lib/NRCPX2BY/"
    },
    "datePublished": "2026-02-05T16:28:41-05:00",
    "dateModified": "2026-02-05T16:29:07-05:00",
    "author": {
        "@type": "Person",
        "name": "Craig B. Bleifer, Jessica L. Vaughn, Ph.D."
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "McGuireWoods LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "The FCA Insider",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.thefcainsider.com/?p=2035",
    "sourceStability": "may-move"
}